Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Dr. Elise Kelly, a veterinarian at Elanco Animal Health, discovered the presence of potentially deadly Echinococcus tapeworms in wild animal feces in her Missouri backyard. This finding highlights a significant but often overlooked threat to both pets and humans. According to an Elanco survey, nearly half of dog owners are unaware that their pets face year-round intestinal worm risks, while 73% prefer preventive protection over reactive treatment. The company promotes Interceptor Plus, a monthly chew that protects dogs against five common types of worms, including heartworm disease, hookworm, roundworm, tapeworm, and whipworm infections.
The Schall Law Firm announces a class action lawsuit against Elanco Animal Health (NYSE:ELAN) for alleged violations of securities laws. The lawsuit covers investors who purchased securities between November 7, 2023 and June 26, 2024. The complaint alleges that Elanco made false and misleading statements about the safety of Zenrelia and overstated the timeline for launching Zenrelia and Credelio Quattro. Affected shareholders have until December 6, 2024 to join the lawsuit. The lawsuit claims investors suffered damages when the market learned the truth about these misrepresentations.
Elanco Animal Health (NYSE: ELAN) has acquired a contract manufacturing facility in Speke, UK, previously owned by TriRx Speke , which was under trading administration. The facility is important for producing farm animal product lines worth $160-180 million in annual revenue, primarily outside the U.S. The acquisition, completed for $25 million in cash, secures a critical component of Elanco's global supply chain. The company expects an adjusted EBITDA headwind of $25-35 million in 2025, mainly affecting gross profit.
Elanco Animal Health (NYSE: ELAN) has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, brings extensive experience in biopharmaceutical development and manufacturing. She previously held leadership positions at Sana Biotechnology and Genentech/Roche. Dr. Ma was recognized as one of the 'Top 20 Women Leaders in Biopharma R&D' by Endpoints News in 2020 and is a Fellow of the American Institute for Medical and Biological Engineering. Her expertise will support Elanco's Innovation, Portfolio and Productivity strategy and development of next-generation pipeline products.
Elanco Animal Health (NYSE: ELAN) reported Q3 2024 revenue of $1,030 million, with 1% organic constant currency growth. The company posted reported net income of $364 million and adjusted net income of $66 million. Adjusted EBITDA was $163 million (15.8% of revenue), with reported EPS of $0.73 and adjusted EPS of $0.13.
The company recorded a pre-tax gain of $640 million from July 2024 aqua business divestiture and tightened its full-year 2024 guidance to revenue of $4,420-4,450 million. Notable achievements include U.S. FDA approvals for Zenrelia and Credelio Quattro. For 2025, Elanco expects mid-single-digit organic revenue growth, with adjusted EBITDA growth in low single digits.
At the recent Reuters Transform Food & Agriculture event, 200 industry leaders discussed key requirements for transforming the future of food. The focus areas included: supply chain integration, developing scalable and profitable innovations for farmers, and maintaining a growth mindset. Katie Cook, VP of Livestock Sustainability and U.S. Farm Animal Marketing, moderated a panel with representatives from various agricultural companies, discussing supply chain collaborations and innovations. A fireside chat with Jackie Klippenstein from Dairy Farmers of America addressed initiatives for reducing and measuring enteric methane emissions, particularly focusing on Scope 3 emissions reductions.
Rigrodsky Law, P.A. has announced an investigation into potential claims against the officers and directors of Elanco Animal Health Incorporated (NYSE:ELAN) on behalf of stockholders. The investigation concerns shareholders who purchased or acquired Elanco shares on or before November 7, 2023. Interested parties are encouraged to visit the law firm's website or contact Leah Wihtelin for more information about the investigation and their rights. This announcement suggests possible legal action related to Elanco's corporate governance or business practices, which could potentially impact shareholders.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced the date for its third quarter 2024 financial results. The company will release its results on Thursday, November 7, 2024, followed by a conference call with the investment community and media at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through a link that will be posted on Elanco's investor relations website. A replay of the call will also be made available on the website shortly after its conclusion.
Elanco Animal Health's CEO, Jeff Simmons, discusses a climate solution for the dairy and meat industry in a Fast Company article. He highlights that cattle can be part of addressing global hunger and climate issues. The FDA recently approved Bovaer® (3-NOP), Elanco's methane-reducing feed ingredient for lactating dairy cattle. This product can lower methane emissions by around 30%, equivalent to 1.2 metric tons of CO2e emissions annually per cow.
Simmons emphasizes the importance of climate neutral farming and introduces tools like UpLook for measuring greenhouse gas emissions and Athian's carbon insetting marketplace. These innovations aim to help farmers reduce, measure, and monetize emission reductions, benefiting the entire food chain. The goal is to achieve climate neutral livestock farms within this decade, making U.S. farmers more competitive while helping food companies meet their emissions goals.
Elanco Animal Health (NYSE: ELAN) has received FDA approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the broadest canine oral parasiticide, offering protection against six parasites: fleas, ticks, heartworms, roundworms, hookworms, and tapeworms. This product is the first to combine four active ingredients in a single, monthly chewable tablet for dogs aged eight weeks and older. Credelio Quattro starts killing ticks and fleas within 4 hours, achieving over 99% flea kill within 8 hours and 100% within the first day, remaining effective for a month. It provides 100% protection against heartworm disease from the first dose and is effective against zoonotic parasites, which can infect both pets and humans. Elanco plans to launch Credelio Quattro in Q1 2025, joining its existing portfolio of parasiticides, including Seresto® and Advantage®.
FAQ
What is the current stock price of Elanco Animal Health Incorporated (ELAN)?
What is the market cap of Elanco Animal Health Incorporated (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?
How does Elanco support the health and wellness of pets?
